Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study

被引：12

作者：

Piccaluga, Pier Paolo ^{[1
]}

Malagola, Michele ^{[2
]}

Rondoni, Michela ^{[1
]}

Arpinati, Mario ^{[1
]}

Paolini, Stefania ^{[1
]}

Candoni, Anna ^{[1
]}

Fanin, Renato ^{[3
]}

Messa, Emanuela ^{[4
]}

Pirrotta, Maria Teresa ^{[5
]}

Lauria, Francesco ^{[5
]}

Visani, Giuseppe ^{[6
]}

Alberti, Daniele

Rancati, Francesca

Vinaccia, Vincenza ^{[7
]}

Russo, Domenico

Saglio, Giuseppe ^{[4
]}

Baccarani, Michele ^{[1
]}

Martinelli, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Hosp, Inst Hematol & Med Oncol L & A Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy

[2] Univ Brescia, Dept Hematol, Brescia, Italy

[3] Univ Udine, Dept Hematol, Udine, Italy

[4] Univ Torino, Dept Hematol, Orbassano, Turin, Italy

[5] Univ Siena, Dept Hematol, Siena, Italy

[6] Dept Hematol, Pesaro, Italy

[7] Novartis Pharmaceut, Origgio, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 12期

关键词：

imatinib mesylate; acute myeloid leukemia; c-KIT; PDGFRB; targeted therapy;

D O I：

10.3324/haematol.11345

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

引用

页码：1721 / 1722

页数：2

共 50 条

[41] Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study.
Issa, Ghayas C.
Kantarjian, Hagop M.
Short, Nicholas James
Ravandi, Farhad
Huang, Xuelin
Garcia-Manero, Guillermo
Plunkett, William
Gandhi, Varsha
Pemmaraju, Naveen
Daver, Naval Guastad
Borthakur, Gautam
Jain, Nitin
Konopleva, Marina
Estrov, Zeev
Kadia, Tapan M.
Dinardo, Courtney Denton
Brandt, Mark
O'Brien, Susan Mary
Cortes, Jorge E.
Jabbour, Elias
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42] A Phase II of Combination D aunorubicin and Cytarabine (A ra-c) and Nilotinib (TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results
Al-Kali, Aref
Tibes, Raoul
Palmer, Jeanne
Alkhateeb, Hassan B.
Atherton, Pamela
Yan, Fei
Liu, Shujun
He, Rong
Hashmi, Shahrukh K.
Litzow, Mark R.
BLOOD, 2015, 126 (23)
[43] Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
Johnson, JR
Bross, P
Cohen, M
Rothmann, M
Chen, G
Zajicek, A
Gobburu, J
Rahman, A
Staten, A
Pazdur, R
CLINICAL CANCER RESEARCH, 2003, 9 (06) : 1972 - 1979
[44] A PHASE II STUDY OF IMATINIB MESYLATE AS ADJUVANT TREATMENT FOR CURATIVELY RESECTED HIGH-RISK LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH C-KIT EXON 11 MUTATION
Kang, Y.
Kang, B. W.
Ryu, M.
Im, S.
Park, S. R.
Kang, W. K.
Kim, T. W.
Oh, D.
Jung, K. H.
Lee, J.
ANNALS OF ONCOLOGY, 2008, 19 : 169 - 169
[45] Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
Garcia-Manero, Guillermo
Abaza, Yasmin
Takahashi, Koichi
Medeiros, Bruno C.
Arellano, Martha
Khaled, Samer K.
Patnaik, Mrinal
Odenike, Olatoyosi
Sayar, Hamid
Tummala, Mohan
Patel, Prapti
Maness-Harris, Lori
Stuart, Robert
Traer, Elie
Karamlou, Kasra
Yacoub, Abdulraheem
Ghalie, Richard
Giorgino, Ruben
Atallah, Ehab
BLOOD ADVANCES, 2019, 3 (04) : 508 - 518
[46] Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Roboz, G. J.
Lancet, J. E.
Cripe, L. D.
Kashani, F. Ravandi
List, A. F.
Fox, J. A.
Michelson, G.
Karp, J. E.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[47] A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
Abou Dalle, Iman
Cortes, Jorge E.
Pinnamaneni, Pramod
Lamothe, Betty
Duque, Adolfo Diaz
Randhawa, Jasleen
Pemmaraju, Naveen
Jabbour, Elias
Ferrajoli, Alessandra
Wierda, William G.
Estrov, Zeev
Konopleva, Marina
Ravandi, Farhad
Alvarado, Yesid
Borthakur, Gautam
Gandhi, Varsha
Kantarjian, Hagop M.
ACTA HAEMATOLOGICA, 2018, 140 (01) : 30 - 39
[48] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
Kim, Kunhwa
Kantarjian, Hagop
Borthakur, Gautam
Takahashi, Koichi
Short, Nicholas J.
DiNardo, Courtney D.
Jabbour, Elias J.
Chien, Kelly S.
Daver, Naval
Pemmaraju, Naveen
Jain, Nitin
Adewale, Lade
Montalban-Bravo, Guillermo
Wierda, William G.
Verstovsek, Srdan
Konopleva, Marina
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2021, 138
[49] Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study
Huetter-Kroenke, Marie Luise
Fiedler, Walter
Kuendgen, Andrea
Krauter, Juergen
von Lilienfeld-Toal, Marie
Doehner, Hartmut
Schlenk, Richard F.
HAEMATOLOGICA, 2019, 104 (02) : E63 - E64
[50] Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
Fenaux, Pierre
Gobbi, Marco
Kropf, Patricia L.
Issa, Jean-Pierre J.
Roboz, Gail J.
Mayer, Jiri
Krauter, Juergen
Robak, Tadeusz
Kantarjian, Hagop
Novak, Jan
Jedrzejczak, Wieslaw. W.
Thomas, Xavier
Ojeda-Uribe, Mario
Miyazaki, Yasushi
Min, Yoo Hong
Yeh, Su-Peng
Brandwein, Joseph
Gercheva-Kyuchukova, Liana
Demeter, Judit
Griffiths, Elizabeth
Yee, Karen
Doehner, Konstanze
Hao, Yong
Keer, Harold
Azab, Mohammad
Doehner, Hartmut
BLOOD ADVANCES, 2023, 7 (17) : 5027 - 5037

← 1 2 3 4 5 →